Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
02/23/2017 02/24/2017 02/27/2017 02/28/2017 03/01/2017 Date
248.8(c) 249.3(c) 249.5(c) 249.2(c) 245.9 Last
2 915 307 3 262 422 2 259 733 3 761 051 4 461 158 Volume
-0.24% +0.20% +0.08% -0.12% -1.32% Change
More quotes
Financials ( DKK)
Sales 2017 116 441 M
EBIT 2017 49 994 M
Net income 2017 38 297 M
Finance 2017 14 585 M
Yield 2017 3,04%
Sales 2018 121 896 M
EBIT 2018 52 203 M
Net income 2018 41 239 M
Finance 2018 15 289 M
Yield 2018 3,37%
P/E ratio 2017 16,08
P/E ratio 2018 14,56
EV / Sales2017 4,18x
EV / Sales2018 3,99x
Capitalization 501 531 M
More Financials
Company
Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments.The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related... 
Sector
Pharmaceuticals
Calendar
03/23Shareholder meeting
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
07:18a NOVO NORDISK A/S : Change in Novo Nordisk Executive Management
02/28 NVO INVESTORS ALERT : Lieff Cabraser Reminds Investors of Deadline in Class Acti..
02/28 NOVO NORDISK A/S : files for regulatory approval of once-weekly semaglutide for ..
02/27 NOVO NORDISK A/S : DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds I..
02/27 NVO The Law Offices of Vincent Wong Reminds Investors of a Class Action Invol..
02/27 NOVO NORDISK A/S : Notice for the Annual General Meeting of Novo Nordisk A/S
02/27 NOVO NORDISK A/S : - Share repurchase programme
02/27 11 Key Questions Answered for Rapid, Rigorous and Reproducible Pharmaceutical..
02/25 NOVO NORDISK A/S : Pomerantz Law Firm Reminds Shareholders with Losses on their ..
02/24 NOVO NORDISK A/S : Researchers from Novo Nordisk Report Details of New Studies a..
More news
Sector news : Pharmaceuticals - NEC
02:25p MYLAN : Generic drugmaker Mylan's profit benefits from Meda buy
12:41p Bayer sells 11 percent of Covestro for 1.46 billion euros
11:18a Banks, basic resources lift European shares on Trump-trade
09:44aDJCovestro Shares Nosedive After Bayer Reduces Stake
09:39aDJVENTURE LIFE : Appoints Abbott Laboratories' Adrian Crockett as CFO
More sector news : Pharmaceuticals - NEC
Latest Tweets
02:39p$NVO - Novo Nordisk replaces head of North American operations  
02:38pNovo Nordisk A/S North America Head Quits, Replacement Named  
01:52pNovo Nordisk's North American chief Jakob Riis, passed over for the CEO job, ..
3
01:43pNovo Nordisk replaces head of North American operations -  
12:40pNovo Nordisk replaces head of North American operations  
More tweets
Qtime:39
News from SeekingAlpha
07:18a IMF FEBRUARY BUYS : 16 Additions To My Funds
02/28 Industry's Rare Disease Moves Pay Off
02/27 It's Not The Right Time To Buy Novo Nordisk
02/24 SYNERGY : 3 Scenarios, 1 Choice
02/21 A Time To Buy Novo Nordisk
Advertisement
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 273  DKK
Spread / Average Target 9,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-2.04%71 582
JOHNSON & JOHNSON6.24%332 993
ROCHE HOLDING LTD.4.73%209 283
PFIZER INC.5.48%204 030
NOVARTIS AG5.06%203 039
MERCK & CO., INC.12.38%181 558
More Results